Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine
Open accessPublished version of a preprint
The DOI matches its Crossref record; 24 of the 30 references it cites were found in a registry or an index; 11 of the 12 sources its claims cite were checked for support.
Abstract
The duration of protection of the third (booster) dose of the BioNTech/Pfizer BNT162b2 mRNA Coronavirus Disease 2019 vaccine has been the subject of recent investigations, as global discussions around the necessity and effectiveness of a fourth dose are already underway. By conducting a retrospective study implementing a test-negative case-control design, analyzing 546,924 PCR tests performed throughout January 2022 by 389,265 persons who received at least two doses, we find that the effectiveness in each month-since-vaccination decreases significantly. Compared to those vaccinated five months prior to the outcome period, on August 2021, relative protection against infection waned from 53.4% a month after vaccination to 16.5% three months after vaccination. These results suggest that there is a significant waning of vaccine effectiveness against the Omicron variant of the third dose of the BNT162b2 vaccine within a few months after administration. Additional information could assist to comprehensively estimate the effectiveness of the three-dose-strategy.
Overview
CoChat Summary
TL;DR
In a retrospective test-negative case-control study in Maccabi Healthcare Services during the Omicron-dominant period in January 2022, third-dose BNT162b2 effectiveness against infection declined from 53.4% one month after vaccination to 16.5% three months after vaccination, relative to August 2021 booster recipients. Waning against severe disease was not statistically significant, with the authors noting small numbers.
Key findings
- Among 546,924 PCR tests by 389,265 eligible MHS members from January 1–21, 2022, adjusted third-dose VE against SARS-CoV-2 infection compared with August 2021 booster recipients was 53.4% (95% CI 47.7–58.6) for December 2021 vaccinees, 35.7% (29.8–41.2) for November 2021 vaccinees, 16.5% (13.0–19.9) for October 2021 vaccinees, and 3.6% (0.6–6.5) for September 2021 vaccinees.
- In the marginal-effectiveness analysis versus two-dose-only vaccinees, booster effectiveness against infection peaked at 59.4% (95% CI 54.9–63.5) one month after vaccination and declined to 16% (95% CI 12.3–19.5) five months after vaccination.
- For severe disease, the main analysis did not reach significance for decreasing VE against hospitalization or death as time since inoculation increased; the paper states the raw numbers were too small for a reliable conclusion. Marginal severe-disease VE declined from 72.2% (95% CI 37.8–87.6) at 3 months to 54.5% (95% CI 13.4–76.1) at 5 months, again with small numbers.
- During the Omicron period, 101,737 breakthrough infections and 482 breakthrough infections resulting in hospitalization or death were detected; among August 2021 booster recipients there were 30,870 infections, 208 hospitalizations, and 9 deaths, while among December 2021 booster recipients there were 1,082 infections, 4 hospitalizations, and zero deaths.
Methods
- Retrospective test-negative case-control study using Maccabi Healthcare Services data; included MHS members aged 16 or older who received at least two BNT162b2 doses by August 1, 2021, with outcomes evaluated January 1–21, 2022, an Omicron-dominant period in Israel.
- Cases were PCR-positive persons or persons with severe COVID-19 during follow-up; controls were PCR-negative persons; 1:1 matching was based on sex, age group, geographic statistical area, calendrical week of testing, and month of second-dose receipt; conditional logistic regression was adjusted for comorbidities, and VE was calculated as 100% × [1 − odds ratio].
- Additional analyses included an unmatched GEE logistic regression allowing multiple negative tests, inclusion of tests 0–6 days after a fourth dose, changing the reference group to two-dose-only vaccinees, inclusion of individuals with hybrid immunity, and assessment of control-group representativeness.
Limitations
- Stated in the paper: potential bias from healthcare-related testing behavior, especially with changing Israeli testing policies during the Omicron surge; the August 2021 comparison group was generally older and sicker; residual confounding by indication was considered less likely after matching/adjustment, though effect modification was seen for obesity; Omicron dominance meant waning against other strains could not be evaluated; and the database lacked reason for testing.
- Stated in the paper: severe-disease analyses were limited by small numbers of hospitalizations and deaths, preventing reliable conclusions about waning against severe outcomes.
- Evident from the text: the observational design cannot establish causation, and the fourth-dose exclusion/sensitivity analyses indicate that vaccination-status definitions and timing choices may affect estimates.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
6 Valid · 0 Not valid · 1 Not checked · 27 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, as by the outcome period of January 2022 most of Israel’s population had already received the booster, the reference group of those unvaccinated is admittedly prone to bias, as has been discussed in the previous papers11.”
§ Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine > Methods > Design and statistical analysis
What the sources say
- Partly supportedcites [11] Patalon, T. et al. Odds of Testing Positive for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA Vaccine. JAMA Intern Med. 182, 179–184 (2021). sourceExperimental — accuracy not yet measured
The Limitations section acknowledges potential bias in the booster comparison, including differences in testing behavior and possible confounding because chronically ill patients were prioritized. It does not attribute bias to most Israelis having received a booster. The Data Collection and Study Population section says the analysis ended in October 2021, so the paper does not assess the claimed January 2022 outcome period. (LLM, conf=0.78)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, it seems that effectiveness could be declining faster than that of the second dose6,19.”
§ Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine > Discussion
What the sources say
- Partly supportedcites [6] Chemaitelly, H. et al. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. N. Engl. J. Med 385, e83 (2021). sourceExperimental — accuracy not yet measured
The Results section reports that effectiveness against infection declined after the second dose, accelerating after the fourth month. It does not assess effectiveness after a third dose or compare the rates of decline, so it cannot support the claim that third-dose effectiveness may decline faster. (LLM, conf=0.85)
- Partly supportedcites [19] Goldberg, Y. et al. Waning Immunity after the BNT162b2 Vaccine in Israel. N. Engl. J. Med 385, e85 (2021). sourceExperimental — accuracy not yet measured
The Results (Descriptive Analysis; page unavailable) and Discussion report waning immunity after the second dose. The Discussion mentions a third dose only as a booster approved in response to those findings; it does not assess third-dose effectiveness or compare its rate of decline with that after the second dose. (LLM, conf=0.86)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The faster decline might partly be explain by an escape of the Omicron variant from neutralizing antibody responses20, though further variant-specific evidence need to be established.”
§ Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine > Discussion
What the sources say
- Partly supportedcites [20] Girard, B. et al. mRNA-1273 Vaccine-elicited Neutralization of SARS-CoV-2 Omicron in Adolescents and Children. medRxiv Prepr Serv Heal Sci. (2022). https://doi.org/10.1101/2022.01.24.22269666. sourceExperimental — accuracy not yet measured
The Results (page not provided) show substantially lower neutralizing titers against Omicron than against D614G four weeks after a second mRNA-1273 dose, supporting the antibody-escape part of the explanation. The Methods and Conclusions (pages not provided) make clear that this paper assessed two-dose responses and lacked effectiveness and longer-term data; it does not establish a faster decline in third-dose effectiveness or link that decline to antibody escape. (LLM, conf=0.88)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As for severe disease, we did not reach significance implying a decreasing VE against hospitalizations or death as a function of time-since-inoculation (Table 2 and S1).”
§ Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine > Results > Main analysis–test-negative case-control design
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“None of the comorbidities were significantly related to the odds of testing positive (Table S1).”
§ Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine > Results > Main analysis–test-negative case-control design
plainn = 110,918- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
18 more claims
Create a free account to see all 34 claims and every source verdict.
- Probably not a substantial claim. 5
- It may state two separate claims as one. 6
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Notwithstanding these limitations, findings were consistent with those of other studies of vaccine effectiveness against omicron infection (BA.1 or BA.2 subvariants were not specified).27,32-36”
From Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections (2022) · cites this paper as [34]
In the citing paper
“Observational data from Israel demonstrated waning of mRNA booster protection against infection.6”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine > Results > Main analysis–test-negative case-control design
“was 53.4% (95% Confidence Interval [CI], 47.7–8.6%) compared to those vaccinated early, in August.”
§ Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine > Results > Main analysis–test-negative case-control design
“| Dec. 2021 (−1)‡ | 421 | 864 | 53.4(47.7, 58.6) |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine > Results > Main analysis–test-negative case-control design
“The aOR represents the ratio between the odds of testing positive or having severe COVID-19 during the January 1-21, 2022 period among those vaccinated in August 2021 (the first month of eligibility to the booster shot) and the respective odds in each subsequent month of vaccination.”
§ Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine > Methods > Design and statistical analysis
“The vaccine effectiveness (VE) of the booster in each month, compared to the first month of eligibility for the booster19 (August 2021) was calculated as 100%*[1-(Odds Ratio)] for each of the month-since-vaccination categories.”
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527 · cited 1×
“The 7-day cutoff was chosen based on previous research the BNT162b2 vaccine effectivenesss.(1,11) The second outcome referred to a severe disease, defined as a COVID-19-related hospitalization or death occurring within the same time frame.”
MethodEffectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern
Andrews, N., Stowe, J., Kirsebom, F., Toffa, S., Rickeard, T., Gallagher, E., Gower, C., Kall, M., Groves, N., O’Connell, A.-M., et al. (2021) · doi:10.1101/2021.12.14.21267615 · Cited by 2,420
Perineuronal nets stabilize the grid cell network
Christensen, A. C., Lensjø, K. K., Lepperød, M. E., Dragly, S.-A., Sutterud, H., Blackstad, J. S., Fyhn, M., & Hafting, T. (2021) · Nature Communications · doi:10.1038/s41467-020-20241-w · Cited by 1,865
Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
Levin, E. G., Lustig, Y., Cohen, C., Fluss, R., Indenbaum, V., Amit, S., Doolman, R., Asraf, K., Mendelson, E., Ziv, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114583 · Cited by 1,703
Using Generalized Estimating Equations for Longitudinal Data Analysis
Ballinger, G. A. (2004) · Organizational Research Methods · doi:10.1177/1094428104263672 · Cited by 1,567
Haas, E. J., Angulo, F. J., McLaughlin, J. M., Anis, E., Singer, S. R., Khan, F., Brooks, N., Smaja, M., Mircus, G., Pan, K., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00947-8 · Cited by 1,564
Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
Bar-On, Y. M., Goldberg, Y., Mandel, M., Bodenheimer, O., Freedman, L., Kalkstein, N., Mizrahi, B., Alroy-Preis, S., Ash, N., Milo, R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114255 · Cited by 1,169 · cited 1×
“Studies have demonstrated that the third dose increases immunogenicity against SARS-CoV-2 as reflected by a rapid and broad immune response to the third BNT162b2 dose.(7,11) Our results suggested a time dependent response with a primary increase in VE followed by waning of effectiveness.”
BackgroundWaning Immunity after the BNT162b2 Vaccine in Israel
Goldberg, Y., Mandel, M., Bar-On, Y. M., Bodenheimer, O., Freedman, L., Haas, E. J., Milo, R., Alroy-Preis, S., Ash, N., & Huppert, A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114228 · Cited by 1,034 · cited 1×
“However, it seems that effectiveness could be declining faster than that of the second dose.(6,17) The faster decline might partly be explain by an escape of the Omicron variant from neutralizing antibody responses,(18) though further variant-specific evidence need to be established.”
BackgroundCoresh, J., Turin, T. C., Matsushita, K., Sang, Y., Ballew, S. H., Appel, L. J., Arima, H., Chadban, S. J., Cirillo, M., Djurdjev, O., et al. (2014) · JAMA · doi:10.1001/jama.2014.6634 · Cited by 988
Cited by
Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections
Altarawneh, H. N., Chemaitelly, H., Ayoub, H. H., Tang, P., Hasan, M. R., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Coyle, P., Al-Kanaani, Z., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203965 · Cited by 551
Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar
Chemaitelly, H., Ayoub, H. H., AlMukdad, S., Coyle, P., Tang, P., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Hasan, M. R., Al-Kanaani, Z., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30895-3 · Cited by 228
Yu, W., Guo, Y., Zhang, S., Kong, Y., Shen, Z., & Zhang, J. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28066 · Cited by 117
Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age
Muñoz, F. M., Sher, L., Sabharwal, C., Gurtman, A., Xu, X., Kitchin, N. R. E., Lockhart, S. P., Riesenberg, R. A., Sexter, J. M., Czajka, H., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2211031 · Cited by 111
“Data are available that suggest waning effectiveness of a third BNT162b2 dose in older adolescents and adults within a few months after administration, yet administration of a fourth dose given at least 4 months after dose 3 to older adults increases protection against SARS-CoV-2 infection, symptomatic and severe Covi…”
BackgroundSeverity of the Omicron SARS‐CoV ‐2 variant compared with the previous lineages: A systematic review
Arabi, M., Al-Najjar, Y. A., Mhaimeed, N., Salameh, M. A., Paul, P., Alanni, J., Abdelati, A. A., Laswi, I., Khanjar, B., Al‐Ali, D., et al. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17747 · Cited by 108
Metadata
- Authors
- Patalon, T., Saciuk, Y., Peretz, A., Perez, G., Lurie, Y., Maor, Y., & Gazit, S.
- Affiliations
- Maccabi Healthcare Services (IL)
- Shaare Zedek Medical Center (IL)
- Corresponding author
- Patalon, Tal
- Venue
- Nature Communications
- Published
- 2022-06-09
- Volume
- 13
- Issue
- 1
- Pages
- 3203-3203
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC9184525
- OpenAlex
- W4281648214
- Cited by
- 143
- References
- 30
- Citations by year
- 2026: 4 · 2025: 15 · 2024: 25 · 2023: 56 · 2022: 43
- FWCI
- 16.96
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- medRxiv (acceptedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Keywords
- BNT162b2 mRNA vaccine, COVID-19 vaccines, booster vaccination, waning vaccine effectiveness, Omicron variant, COVID-19 pandemic, test-negative case-control, PCR testing, duration of protection
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, BNT162 Vaccine, Humans, Retrospective Studies, RNA, Messenger
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine. https://app.cochat.ai/papers/10.1038/s41467-022-30884-6
- The paper
- Patalon, T., Saciuk, Y., Peretz, A., Perez, G., Lurie, Y., Maor, Y., & Gazit, S. (2022). Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine. Nature Communications. https://doi.org/10.1038/s41467-022-30884-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.